At a glance
ClinicalIndex Comparison RecordPhase 2Active· 41 enrolled
Drug / intervention
Pembrolizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas
Academic and Community Cancer Research United·interventional·Posted Oct 31, 2016·Updated Aug 22, 2024
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Pembrolizumab for Metastatic Small Intestinal Adenocarcinoma and 2 related conditions. Active but no longer recruiting, targeting 41 participants across 8 sites.
Detailed Summary
This phase II trial studies how well pembrolizumab works in treating patients with small bowel adenocarcinoma that has spread to other places in the body or that cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma, Unresectable Small Intestinal Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2ActiveOverdue
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartMar 2017
Primary CompletionJan 2019
Study CompletionDec 2024
TodayJul 2026
First PostedOct 31, 2016
Enrollment StartMar 24, 2017
Primary CompletionJan 31, 2019
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.7 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Pembrolizumabbiological
Given IV